Additionally, Kamphorst et al. ascertained that within the cohort of patients with advanced NSCLC, PD-1+CD8+ T cell responses were either delayed or absent in 70% of those experiencing disease progression, while 80% of the patients who positively responded to immunotherapy exhibited PD-1+CD8+ T cell responses within four weeks of treatment initiation (78). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.